Prothena Corporation plc (PRTA)’s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) – The EN Herald

Both Prothena Corporation plc (NASDAQ:PRTA) and Neuralstem Inc. (NASDAQ:CUR) are Biotechnology companies, competing one another. We will compare their risk, analyst recommendations, profitability, dividends, earnings and valuation, institutional ownership.

Valuation & Earnings

Table 1 demonstrates Prothena Corporation plc and Neuralstem Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 provides Prothena Corporation plc and Neuralstem Inc.s net margins, return on assets and return on equity.

Volatility and Risk

A 2.24 beta indicates that Prothena Corporation plc is 124.00% more volatile compared to Standard and Poors 500. Neuralstem Inc. on the other hand, has 1.94 beta which makes it 94.00% more volatile compared to Standard and Poors 500.

Liquidity

Prothena Corporation plcs Current Ratio is 27.9 while its Quick Ratio is 27.9. On the competitive side is, Neuralstem Inc. which has a 3.8 Current Ratio and a 3.8 Quick Ratio. Prothena Corporation plc is better positioned to pay off short and long-term obligations compared to Neuralstem Inc.

Insider and Institutional Ownership

Roughly 92.7% of Prothena Corporation plc shares are held by institutional investors while 4.9% of Neuralstem Inc. are owned by institutional investors. Prothena Corporation plcs share held by insiders are 90.1%. Competitively, Neuralstem Inc. has 1% of its share held by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Prothena Corporation plc has stronger performance than Neuralstem Inc.

Summary

Prothena Corporation plc beats Neuralstem Inc. on 7 of the 7 factors.

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. It is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002 that has completed Phase Ib clinical trial for treating Parkinsons disease and other related synucleinopathies; PRX003, a monoclonal antibody that is in Phase Ib for the treatment of psoriasis and other inflammatory diseases; and PRX004, a monoclonal antibody that is under preclinical development. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein. Prothena Corporation plc was incorporated in 2012 and is headquartered in Dn Laoghaire, Ireland.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Prothena Corporation plc (PRTA)'s Financial Results Comparing With Neuralstem Inc. (NASDAQ:CUR) - The EN Herald